ADAnneleen Daemen

Anneleen Daemen

*This is an algorithmically generated author record based on publicly available information.

Anneleen Daemen has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Lil Valentin

    Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden

    2 shared publications
  • A. Czekierdowski

    Department of Gynecological Oncology and Gynecology, Medical University, Lublin, Poland

    1 shared publication
  • A. Rossi

    Department of Obstetrics and Gynecology, Università degli Studi di Udine, Italy

    1 shared publication
  • Alan Ashworth

    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK

    1 shared publication
  • Amy Rappaport

    Discovery Oncology, Genentech Inc., South San Francisco, California

    1 shared publication
  • Anju Singh

    Department of Environmental Health Science and Engineering, Johns Hopkins University School of Public Health, Baltimore, Maryland

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

    by Anju Singh, Anneleen Daemen, Dorothee Nickles, Sang-Min Jeon, Oded Foreman, Kuladeep Sudini, Florian Gnad, Stephane Lajoie, Naina Gour, Wayne Mitzner, et al.

    Purpose: Stabilization of the transcription factor NRF2 through genomic alterations in KEAP1 and NFE2L2 occurs in a quarter of patients with lung adenocarcinoma and a third of patients with lung squamous cell carcinoma. In lung adenocarcinoma, KEAP1 loss often co-occurs with STK11 loss and KRAS-activating alterations. Despite its prevalence, the impact of NRF2 activation on tumor progression and patient outcomes is not fully defined. Experimental Design: We model NRF2 activation, STK11 loss, and KRAS activation in vivo using novel genetically engineered mouse models. Furthermore, we derive a NRF2 activation signature from human non–small cell lung tumors that we use to dissect how these genomic events impact outcomes and immune contexture of participants in the OAK and IMpower131 immunotherapy trials. Results: Our in vivo data reveal roles for NRF2 activation in (i) promoting rapid-onset, multifocal intrabronchiolar carcinomas, leading to lethal pulmonary dysfunction, and (ii) decreasing elevated redox stress in KRAS-mutant, STK11-null tumors. In patients with nonsquamous tumors, the NRF2 signature is negatively prognostic independently of STK11 loss. Patients with lung squamous cell carcinoma with low NRF2 signature survive longer when receiving anti–PD-L1 treatment. Conclusions: Our in vivo modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with STK11 loss and KRAS activation to promote aggressive lung adenocarcinoma. In patients, oncogenic events alter the tumor immune contexture, possibly having an impact on treatment responses. Importantly, patients with NRF2-activated nonsquamous or squamous tumors have poor prognosis and show limited response to anti–PD-L1 treatment.


  • Open Access

    Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

    by Anneleen Daemen, Denise M. Wolf, James E. Korkola, Obi L. Griffith, Jessica R. Frankum, Rachel Brough, Lakshmi R. Jakkula, Nicholas J. Wang, Rachael Natrajan, Jorge S. Reis-Filho, et al.

    Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in DNA repair. PARP inhibitors can act as chemosensitizers, or operate on the principle of synthetic lethality when used as single agent. Clinical trials have shown drugs in this class to be promising for BRCA mutation carriers. We postulated that inability to demonstrate response in non-BRCA carriers in which BRCA is inactivated by other mechanisms or with deficiency in homologous recombination for DNA repair is due to lack of molecular markers that define a responding subpopulation. We identified candidate markers for this purpose for olaparib (AstraZeneca) by measuring inhibitory effects of nine concentrations of olaparib in 22 breast cancer cell lines and identifying features in transcriptional and genome copy number profiles that were significantly correlated with response. We emphasized in this discovery process genes involved in DNA repair. We found that the cell lines that were sensitive to olaparib had a significant lower copy number of BRCA1 compared to the resistant cell lines (p value 0.012). In addition, we discovered seven genes from DNA repair pathways whose transcriptional levels were associated with response. These included five genes (BRCA1, MRE11A, NBS1, TDG, and XPA) whose transcript levels were associated with resistance and two genes (CHEK2 and MK2) whose transcript levels were associated with sensitivity. We developed an algorithm to predict response using the seven-gene transcription levels and applied it to 1,846 invasive breast cancer samples from 8 U133A/plus 2 (Affymetrix) data sets and found that 8–21 % of patients would be predicted to be responsive to olaparib. A similar response frequency was predicted in 536 samples analyzed on an Agilent platform. Importantly, tumors predicted to respond were enriched in basal subtype tumors. Our studies support clinical evaluation of the utility of our seven-gene signature as a predictor of response to olaparib.


  • Improved modeling of clinical data with kernel methods

    by Anneleen Daemen, Dirk Timmerman, Thierry Van Den Bosch, Cecilia Bottomley, Emma Kirk, Caroline Van Holsbeke, Lil Valentin, Tom Bourne, Bart De Moor


  • Open Access

    Improving the preoperative classification of adnexal masses as benign or malignant by second‐stage tests

    by A. Daemen, L. Valentin, R. Fruscio, C. Van Holsbeke, G. B. Melis, S. Guerriero, A. Czekierdowski, D. Jurkovic, W. Ombelet, A. Rossi, et al.

    Objective The aim of this study was to establish when a second‐stage diagnostic test may be of value in cases where a primary diagnostic test has given an uncertain diagnosis of the benign or malignant nature of an adnexal mass. Methods The diagnostic performance with regard to discrimination between benign and malignant adnexal masses for mathematical models including ultrasound variables and for subjective evaluation of ultrasound findings by an experienced ultrasound examiner was expressed as area under the receiver–operating characteristics curve (AUC), sensitivity and specificity. These were calculated for the total study population of 1938 patients with an adnexal mass as well as for subpopulations defined by the certainty with which the diagnosis of benignity or malignancy was made. The effect of applying a second‐stage test to the tumors where risk estimation was uncertain was determined. Results The best mathematical model (LR1) had an AUC of 0.95, sensitivity of 92% and specificity of 84% when applied to all tumors. When model LR1 was applied to the 10% of tumors in which the calculated risk fell closest to the risk cut‐off of the model, the AUC was 0.59, sensitivity 90% and specificity 21%. A strategy where subjective evaluation was used to classify these 10% of tumors for which LR1 performed poorly and where LR1 was used in the other 90% of tumors resulted in a sensitivity of 91% and specificity of 90%. Applying subjective evaluation to all tumors yielded an AUC of 0.95, sensitivity of 90% and specificity of 93%. Sensitivity was 81% and specificity 47% for those patients where the ultrasound examiner was uncertain about the diagnosis (n = 115; 5.9%). No mathematical model performed better than did subjective evaluation among the 115 tumors where the ultrasound examiner was uncertain. Conclusion When model LR1 is used as a primary test for discriminating between benign and malignant adnexal masses, the use of subjective evaluation of ultrasound findings by an experienced examiner as a second‐stage test in the 10% of cases for which the model yields a risk of malignancy closest to its risk cut‐off will improve specificity without substantially decreasing sensitivity. However, none of the models tested proved suitable as a second‐stage test in tumors where subjective evaluation yielded an uncertain result. Copyright © 2010 ISUOG. Published by John Wiley & Sons, Ltd.


    • 1 April 2009
      • Vol. 29  (4) , 1039-45

    The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles.

    by Isabelle Cadron, Toon Van Gorp, Frédéric Amant, Ignace Vergote, Philippe Moerman, Etienne Waelkens, Anneleen Daemen, Raf Van De Plas, Bart De Moor, Robert Zeillinger

    There is a strong need for prognostic biomarkers in ovarian cancer patients due to the heterogeneous responses on current treatment modalities. This study investigates the feasibility of combining laser microdissection (LMD) and surface enhanced laser desorption ionization-time of flight mass spectrometry (SELDI-TOF MS) in ovarian cancer tissue to obtain protein profiles. Ideal conditions for preparing a protein lysate were determined and subsequently analysed on SELDI-TOF MS. Applying these protocols on tissue of 9 ovarian cancer patients showed different protein profiles between platinum sensitive and resistant patients. This shows that combining optimised protocols for LMD with SELDI-TOF MS can be used to obtain discriminatory protein profiles. However, studies with large patient numbers and validation sets are essential to identify reliable biomarkers using this approach.